Previous 10 | Next 10 |
In an experimental back of the eye, autoimmune uveitis (EAU) model to be reported in a poster presentation at ARVO 2019, nomacopan (Coversin) and its long acting variants administered intravitreally, reported: ○ Significant improvement in clinical scoring versus control ɜ...
Akari Therapeutics ( AKTX ) announced that it had achieved positive results from its phase 2 study using its drug Nomacopan (Coversin) to treat patients with bullous pemphigoid ((BP)). This could provide patients with a new treatment option other than current drugs that cause adverse eve...
Arrowhead Pharmaceuticals ( ARWR ) - The company announced that dosing has begun in a new triple combination cohort utilizing JNJ-3989 plus additional undisclosed agents in the ongoing phase 1/2 study in patients with chronic hepatitis B virus. As a result of opening this new cohort, Arrowhe...
Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid (BP) resulted in no drug-related adverse events and rapid reduction in BP Disease Area Index (BPDAI) score and blistering in ongoing Phase II clinical trial Pivotal clinical trial for pediat...
CORAL GABLES, FL / ACCESSWIRE / April 23, 2019 / The stock market is on the verge of setting new record highs today April 23, 2019. Previous highs for the SPY from 2018 was $293.94 and today Tuesday 4/23/2019 the SPY has already hit highs of $293.14. Positive sentiment surrounding global tr...
Gainers: Atossa Genetics (NASDAQ: ATOS ) +28% . Immunic (NASDAQ: IMUX ) +22% . Akari Therapeutics (NASDAQ: AKTX ) +19% . Superconductor Technologies (NASDAQ: SCON ) +18% . X4 Pharmaceuticals (NASDAQ: XFOR ) +17% . Hasbro (NASDAQ: HAS ) +16% . Twitter (NYSE: TWTR ) +16% . Trova...
TrovaGene (NASDAQ: TROV ) +22% on positive onvansertib data . More news on: TrovaGene, Inc., Akari Therapeutics, Plc, Hasbro, Inc., Stocks on the move, Read more ...
Nano cap Akari Therapeutics (NASDAQ: AKTX ) is up 25% premarket on increased volume in reaction to positive data from a Phase 2 clinical trial evaluating second-generation complement inhibitor Coversin (nomacopan) in patients with a rare inflammatory skin condition called bull...
NEW YORK and LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces posit...
Poster to be presented on back-of-the-eye program including data from uveitis preclinical model Interim data expected from Akari’s Phase I/II clinical trial in atopic keratoconjunctivitis (AKC), a surface of the eye inflammatory disease NEW YORK and LONDON, March 27, 2019 ...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
Akari Therapeutics Plc Website:
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotec...
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is ...
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan fo...